BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Thyroid cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for thyroid cancer: 47 (34 sponsors; 6 newly posted in the last 180 days, 2 stopped in the last 180 days; 2 new-entrant sponsors). Momentum score 3.2, rank 90 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 1, Phase 1 14, Phase 2 12, Phase 3 5, Phase 4 5, N/A 10.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Exelixis EXEL4P3 2, P4 1, P1 110
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3P4 1, NA 1, P3 101
Novartis Pharmaceuticals NVS3NA 1, P3 1, P1 111
Loxo Oncology, Inc.1P3 100
Eli Lilly and Company LLY5P2 3, P1 1, P4 110
Novo Nordisk A/S NVO2NA 211
Pfizer PFE2P1 200
AccSalus Biosciences, Inc.1P1 100
Adela, Inc1NA 101
AffyImmune Therapeutics, Inc.1P1 100
Alpha Fusion Inc.1P1 100
Apollomics Inc. APLM1P2 100
AstraZeneca AZN1NA 100
Bayer1NA 100
Beijing Scitech-Mq Pharmaceuticals Limited1P2 100
Degron Therapeutics Co.1P1 100
Erasca, Inc. ERAS1P1 100
FindCure Biosciences (ZhongShan) Co., Ltd.1EARLY_P1 101
Fore Biotherapeutics1P2 100
Hoffmann-La Roche1P2 100
Jazz Pharmaceuticals JAZZ1P1 100
Merck Sharp & Dohme LLC MRK1P2 101
ModeX Therapeutics, An OPKO Health Company1P2 100
Pierre Fabre Medicament1P1 100
Power Life Sciences Inc.1NA 100

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-01 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06860971 A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid CarcinomaThyroid Cancerrecruiting144

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "thyroid cancer"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.